1. Catalog
  2. Nodes
  3. a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor")

Equivalencies: 0 | Classes: 0 | Children: 5 | Explore

Entity

Name
EC 3.1.1.7 (acetylcholinesterase) inhibitor
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 2

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. v1.0.0

This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System v1.0.0

In-Edges 7

a(CHEBI:donepezil) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Appears in Networks:

a(CHEBI:galanthamine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Appears in Networks:

a(CHEBI:rivastigmine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Appears in Networks:

a(CHEBI:tacrine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Appears in Networks:

a(MESH:"Cardiovascular System") association a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia. PubMed:24511233

Appears in Networks:

a(MESH:"Gastrointestinal Tract") association a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia. PubMed:24511233

Appears in Networks:

a(CHEBI:galanthamine) isA a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") View Subject | View Object

Appears in Networks:

Out-Edges 9

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases bp(GO:"synaptic transmission, cholinergic") View Subject | View Object

The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms. PubMed:24511233

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases bp(GO:cognition) View Subject | View Object

The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms. PubMed:24511233

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases path(MESH:"Mental Processes") View Subject | View Object

The current primary treatments for AD symptoms are acetylcholinesterase inhibitors (AChEIs) such as donepezil, tacrine, galantamine, and rivastigmine, which potentiate cholinergic signaling.18,19 These treatments not only provide improvements in cognitive symptoms associated with AD,20,21 but also show efficacy in treating the psychiatric symptoms. PubMed:24511233

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") association a(MESH:"Cardiovascular System") View Subject | View Object

Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia. PubMed:24511233

Appears in Networks:

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") association a(MESH:"Gastrointestinal Tract") View Subject | View Object

Unfortunately, cardiovascular and gastrointestinal side effects are often observed with these treatments, effects thought to be mediated by peripherally located ACh receptors. Despite this, AChEIs remain modestly beneficial for treating AD and other forms of dementia. PubMed:24511233

Appears in Networks:

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") decreases path(MESH:"Alzheimer Disease") View Subject | View Object

The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl), also potentiates nAChRs (66). PubMed:17009926

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") decreases act(p(HGNC:ACHE)) View Subject | View Object

The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl), also potentiates nAChRs (66). PubMed:17009926

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") decreases rxn(reactants(a(CHEBI:acetylcholine)), products(a(CHEBI:acetate), a(CHEBI:choline))) View Subject | View Object

The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl), also potentiates nAChRs (66). PubMed:17009926

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:"EC 3.1.1.7 (acetylcholinesterase) inhibitor") increases act(p(FPLX:CHRN)) View Subject | View Object

The most commonly prescribed treatments for AD are acetylcholinesterase inhibitors, which decrease the hydrolysis rate of ACh and, thereby, enhance cholinergic signaling. One such drug, galantamine (Reminyl), also potentiates nAChRs (66). PubMed:17009926

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.